New drug trial offers hope for tough esophageal cancers
NCT ID NCT06769113
Summary
This study is testing an experimental drug called HLX43 for people with advanced esophageal cancer that has returned or spread after initial treatment stopped working. The trial will enroll 72 participants to see if different doses of HLX43 can shrink tumors and control the cancer while monitoring side effects. This is for patients whose cancer progressed despite standard first-line chemotherapy or immunotherapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shandong Cancer Hospital
RECRUITINGJinan, Shandong, 250117, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.